PDL BioPharma, Inc. (NASDAQ: PDLI) reported Q1 EPS of $0.44, $0.01 worse than the analyst estimate of $0.45. Revenue for the quarter came in at $139.7 million versus the consensus estimate of $130.93 million.

For earnings history and earnings-related data on PDL BioPharma, Inc. (PDLI) click here.